Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUBC: UFT + tamoxifen vs CMF + tamoxifen as adjuvant therapy for node‑positive breast cancer
jRCT1080220048Phase 3
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tegafur + uracil, tamoxifen, cyclophosphamide + methotrexate + fluorouracil, cyclophosphamide, methotrexate and 3 more in breast cancer (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
tegafur + uraciltamoxifencyclophosphamide + methotrexate + fluorouracilcyclophosphamidemethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1080220048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220048.